Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Low influenza vaccine uptake in India despite high mortality rates; manufacturers scaling up production to meet growing ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine (Seqirus) and plasma therapy (Behring ...

influenza. "This merger helped the two companies gain leverage in the market, taking advantage of synergies to cut costs and increase development." On 6 May 2011, Sanofi-Aventis simplified its ...

Sanofi is trailing behind GSK and Pfizer when ... mRNA-based candidates for influenza and acne, and a shot for chlamydia. “The pace of our innovation is buoyed both by a sense of urgency to ...

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Monday, March 24, 2025. Let’s take ...

The U.S. Department of Agriculture (USDA) on Thursday announced a $100M investment to combat the transmission of the bird flu ...

Electronic reminders to encourage older adults in Denmark to get vaccinated against flu may have unintentionally lowered ...

Infectious disease outbreaks have a bad habit of piling on at the worst possible times. The 1918 flu pandemic, also known as the Spanish flu, caught the world by surprise just as the First World War ...